All In Biotech

Drug Trial Radar · NCT00041275

Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Sep 20, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Planned (sponsor's estimate)

Start

May 2002

Primary completion

Jun 2007

Study completion Aug 2011

Sponsor

Lead sponsor
National Medical Research Council (NMRC), SingaporeGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jan 28, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using megestrol may fight liver cancer by blocking the uptake of estrogen. It is not yet known if megestrol is an effective treatment for liver cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in treating patients who have liver cancer that cannot be removed by surgery.

Conditions

  • Liver Cancer

Interventions

  • megestrol acetateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival measured weekly

Locations

12 sites in 10 countries. Site status is shown where the registry gives one.

  • Bangabandhu Sheikh Mujib Medical University

    Dhaka, Bangladesh

  • Yangon General Hospital

    Yangon, Burma

  • Rumah Sakit Sanglah

    Denpasar, Bali, Indonesia

  • Auckland City Hospital

    Auckland, New Zealand

  • Davao Doctors Hospital

    Davao City, Philippines

  • National Cancer Centre - Singapore

    Singapore, Singapore

  • Changi General Hospital

    Singapore, Singapore

  • St. Vincent Hospital

    Suwon, South Korea

  • Chang-Gung Memorial Hospital - Taipei

    Taipei, Taiwan

  • Ramathibodi Hospital

    Bangkok, Thailand

  • National Cancer Institute

    Hà Nội, Vietnam

  • Cho Ray Hospital

    Ho Chi Minh City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.